PMID- 35822538
OWN - NLM
STAT- MEDLINE
DCOM- 20220830
LR  - 20221201
IS  - 1747-6356 (Electronic)
IS  - 1747-6348 (Linking)
VI  - 16
IP  - 7
DP  - 2022 Jul
TI  - Elevated soluble death receptor 5 can predict poor prognosis in patients with 
      acute respiratory distress syndrome.
PG  - 823-832
LID - 10.1080/17476348.2022.2100351 [doi]
AB  - BACKGROUND: The tumor necrosis factor (TNF)-related apoptosis-inducing ligand 
      (TRAIL) and its receptor, death receptor 5 (DR5), participate in pulmonary cell 
      apoptosis. This study aimed to investigate the clinical value of soluble DR5 and 
      TRAIL for prognosis assessment in acute respiratory distress syndrome (ARDS). 
      RESEARCH DESIGN AND METHODS: Serum and bronchoalveolar lavage fluid (BALF) 
      samples were collected from ARDS patients and controls. Patients were followed-up 
      until death or discharge. Soluble DR5, TRAIL, TNF-alpha, soluble receptor for 
      advanced glycation end-products (sRAGE), and albumin levels were measured using 
      the Magnetic Luminex or enzyme-linked immunosorbent assays. Data were analyzed 
      according to their distributions and statistical purposes. RESULTS: Serum and 
      BALF DR5 levels were elevated in patients with ARDS; TRAIL elevation and 
      reduction was observed in BALF and serum, respectively. Serum DR5 was higher in 
      non-survivors compared to survivors. Serum DR5 was positively correlated with 
      serum TNF-alpha and critical illness scores and negatively correlated with serum 
      TRAIL. Serum DR5 exhibited potential for predicting mortality in patients with 
      ARDS. CONCLUSIONS: Serum soluble DR5 elevation, a valuable prognosis predictor in 
      ARDS, may be associated with alveolar epithelial cell apoptosis. TRIAL 
      REGISTRATION: 
      http://www.chictr.org.cn/index.aspx.Uniqueidentifier:ChiCTR-DDD-17013370.
FAU - Qin, Jiangyue
AU  - Qin J
AD  - Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and 
      Department of Respiratory and Critical Care Medicine, West China Hospital of 
      Sichuan University, Chengdu, Sichuan, China.
FAU - Wang, Hao
AU  - Wang H
AD  - Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and 
      Department of Respiratory and Critical Care Medicine, West China Hospital of 
      Sichuan University, Chengdu, Sichuan, China.
FAU - Lyu, Zhuoyao
AU  - Lyu Z
AD  - Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and 
      Department of Respiratory and Critical Care Medicine, West China Hospital of 
      Sichuan University, Chengdu, Sichuan, China.
FAU - Liao, Yue
AU  - Liao Y
AD  - Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and 
      Department of Respiratory and Critical Care Medicine, West China Hospital of 
      Sichuan University, Chengdu, Sichuan, China.
FAU - Zeng, Ni
AU  - Zeng N
AD  - Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and 
      Department of Respiratory and Critical Care Medicine, West China Hospital of 
      Sichuan University, Chengdu, Sichuan, China.
FAU - Wang, Ke
AU  - Wang K
AD  - Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and 
      Department of Respiratory and Critical Care Medicine, West China Hospital of 
      Sichuan University, Chengdu, Sichuan, China.
FAU - Zhou, Yongfang
AU  - Zhou Y
AD  - Department of Critical Care Medicine, West China Hospital of Sichuan University, 
      Chengdu, Sichuan, China.
FAU - Zeng, Zijian
AU  - Zeng Z
AD  - Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and 
      Department of Respiratory and Critical Care Medicine, West China Hospital of 
      Sichuan University, Chengdu, Sichuan, China.
FAU - Liao, Zenglin
AU  - Liao Z
AD  - Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and 
      Department of Respiratory and Critical Care Medicine, West China Hospital of 
      Sichuan University, Chengdu, Sichuan, China.
FAU - Cao, Yufang
AU  - Cao Y
AD  - Department of Critical Care Medicine, Haikou Municipal People's Hospital and 
      Central South University Xiangya School of Medicine Affiliated Haikou Hospital, 
      Haikou, Hainan, China.
FAU - He, Junyun
AU  - He J
AD  - Department of Respiratory Medicine, Hospital of Chengdu Office of People's 
      Government of Tibetan autonomous Region, Chengdu, Sichuan, China.
FAU - Wang, Tao
AU  - Wang T
AD  - Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and 
      Department of Respiratory and Critical Care Medicine, West China Hospital of 
      Sichuan University, Chengdu, Sichuan, China.
FAU - Wen, Fuqiang
AU  - Wen F
AD  - Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and 
      Department of Respiratory and Critical Care Medicine, West China Hospital of 
      Sichuan University, Chengdu, Sichuan, China.
LA  - eng
SI  - ChiCTR/ChiCTR-DDD-17013370
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220721
PL  - England
TA  - Expert Rev Respir Med
JT  - Expert review of respiratory medicine
JID - 101278196
RN  - 0 (Biomarkers)
RN  - 0 (Receptor for Advanced Glycation End Products)
RN  - 0 (Receptors, TNF-Related Apoptosis-Inducing Ligand)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Biomarkers
MH  - Humans
MH  - Prognosis
MH  - Receptor for Advanced Glycation End Products
MH  - *Receptors, TNF-Related Apoptosis-Inducing Ligand/blood
MH  - *Respiratory Distress Syndrome/diagnosis
MH  - Tumor Necrosis Factor-alpha
EDAT- 2022/07/14 06:00
MHDA- 2022/08/31 06:00
CRDT- 2022/07/13 05:53
PHST- 2022/07/14 06:00 [pubmed]
PHST- 2022/08/31 06:00 [medline]
PHST- 2022/07/13 05:53 [entrez]
AID - 10.1080/17476348.2022.2100351 [doi]
PST - ppublish
SO  - Expert Rev Respir Med. 2022 Jul;16(7):823-832. doi: 
      10.1080/17476348.2022.2100351. Epub 2022 Jul 21.